Cornell Researchers Develop Particles That Can Supercharge Immunotherapy
Cornell researchers have developed particles that can supercharge immunotherapy, offering a breakthrough approach to treating resistant cancers. The nanoparticles work in an unexpected dual capacity: they fundamentally alter hostile tumor conditions while amplifying the potency of existing immunotherapy drugs. Survival outcomes in mouse experiments show the efficacy of the newly developed particles. Animals with aggressive melanoma receiving the particles combined with immunotherapy drugs targeting checkpoint proteins and immune signaling molecules lived significantly longer than those getting immunotherapy drugs alone. The particles reshaped conditions inside tumors, enabling the immunotherapy drugs to mount a far more effective assault on cancer cells. The particles, designated Cornell prime dots…
